BioSpace News Archive

Business

Zoetis Announces Third Quarter 2022 Results

Zoetis Inc. (NYSE: ZTS) today reported its financial results for the third quarter of 2022.

November 3, 2022
·
34 min read
Business

Bruker Reports Third Quarter 2022 Financial Results

Bruker Corporation (Nasdaq: BRKR) today announced financial results for its third quarter and for the nine months ended September 30, 2022.

November 3, 2022
·
24 min read
Biotech Beach

New Report from GoodRx Shows Positive Impact of Giving Pharmacists the Power to Prescribe

GoodRx (NASDAQ: GDRX), a leading consumer-focused digital healthcare platform, today released a new report that indicates that policies that expand pharmacists’ prescribing and dispensing authority greatly improve access to critical medications.

November 3, 2022
·
3 min read
Business

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the third quarter ended September 30, 2022.

November 3, 2022
·
18 min read
Business

XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events

XOMA Corporation (Nasdaq: XOMA), a biotech royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of advancing novel therapeutic candidates aimed at improving human health, reported its third quarter 2022 financial results and provided a recent operations update.

November 3, 2022
·
9 min read
Business

BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the third quarter ended September 30, 2022 and provided an update on the Company’s operations.

November 3, 2022
·
26 min read
Drug Development

Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced positive topline data from its pivotal Phase 3 VIITAL study assessing the safety and efficacy of EB-101 for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB).

November 3, 2022
·
10 min read
Drug Development

Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome

Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial and potential commercialization of a new class of drug for patients with Tourette Syndrome.

November 3, 2022
·
5 min read
Business

Zhongchao Inc.'s China Operating Entity, Chongqing Xinjiang Pharmaceutical Co., Ltd. Obtained Pharmaceutical Trade and Medical Device Operation Licenses, Ready to Enter Into Pharmaceuticals Circulation Market

Zhongchao Inc. today announced that one of the China operating entities of which the Company consolidates the financial results with through certain contractual arrangements Chongqing Xinjiang Pharmaceutical Co., Ltd. (“Xinjiang Pharmaceutical”) has obtained a series of pharmaceutical related licenses.

November 3, 2022
·
5 min read
Business

Elevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Elevation Oncology, Inc. today announced financial results for the quarter ended September 30, 2022, and highlighted recent progress.

November 3, 2022
·
8 min read